Sanofi

SanofiSanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

www.sanofi.com

Filters
List of articles in category Sanofi
Title Published Date
Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations 11 October 2021
Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate 29 September 2021
Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development 05 August 2021
Sanofi launches dedicated vaccines mRNA Center of Excellence 29 June 2021
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial 17 May 2021
Sanofi to help manufacture Moderna COVID-19 vaccine, supporting global supply demands 26 April 2021
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate 19 March 2021
Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demands 23 February 2021
Sanofi to provide support to BioNTech in manufacturing their COVID-19 vaccine to help address public health needs 27 January 2021
Sanofi offers to acquire Kiadis for €308 million 05 November 2020
Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine 28 October 2020
Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies 16 October 2020
Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union 18 September 2020
Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate 03 September 2020
Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S. 01 September 2020
Sanofi to acquire Principia Biopharma 18 August 2020
Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients 10 July 2020
Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas 24 June 2020
Sanofi invests to make France its world class center of excellence in vaccine research and production 17 June 2020
Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration 26 May 2020